Reference Document Including The Annual Report

Overview

The report describes BioAlliance Pharma's 2012 progress in oncology and supportive-care medicines, including the Phase III launch of Livatag, continued Phase II recruitment for Validive, and authorization of the AMEP Phase I/II trial. It reports Sitavig approval in eight European countries and new licensing and distribution agreements for Oravig, Loramyc and Sitavig. Its social and environmental section covers employment, health and safety, training, equality, stakeholder relations and waste controls, while excluding greenhouse-gas and energy metrics as not relevant or significant.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2012
Period: Ends 31 December 2012
Publication date: 18 April 2013
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services